title: Medulloblastoma: Molecular Classification-Based Personal Therapeutics.
abstract: Recent advances in cancer genomics have revealed 4 distinct subgroups of medulloblastomas, each with unique transcription profiles, DNA alterations and clinical outcome. Molecular classification of medulloblastomas improves predictions of clinical outcome, allowing more accurate matching of intensity of conventional treatments with chemotherapy and radiation to overall prognosis and setting the stage for the introduction of targeted therapies.
authors.affiliation: Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA.|Harvard Medical School, Boston, MA, 02115, USA.
authors.forename: Tenley C
authors.initials: TC
authors.lastname: Archer
authors.affiliation: Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA.
authors.forename: Elizabeth L
authors.initials: EL
authors.lastname: Mahoney
authors.affiliation: Department of Neurology, Boston Children's Hospital, Boston, MA, 02115, USA. scott.pomeroy@childrens.harvard.edu.|Harvard Medical School, Boston, MA, 02115, USA. scott.pomeroy@childrens.harvard.edu.
authors.forename: Scott L
authors.initials: SL
authors.lastname: Pomeroy
mesh_terms: D002528:Cerebellar Neoplasms / Q000145:classification* / Q000235:genetics* / Q000378:metabolism; D023281:Genomics; D053823:Hedgehog Proteins; D006801:Humans; D008527:Medulloblastoma / Q000145:classification* / Q000235:genetics* / Q000378:metabolism; D009154:Mutation; D057285:Precision Medicine; D015398:Signal Transduction; D060449:Wnt Signaling Pathway
chemical_list: D053823:Hedgehog Proteins; C509239:SHH protein, human
keywords: DNA methylation; Genomic; Group 3; Group 4; MYC; Medulloblastoma; SHH; Subgroups; WHO; WNT